A capitated MSK pathway with shared savings: the numbers behind the deal
You advise a UK health insurer contracting with a consortium of 14 physiotherapy practices to run a musculoskeletal pathway for a defined population of 62,000 members across two regions from 1 July. Proposed terms: a capitated fee of £34 per member per year; a baseline spend of £3.1m set from 2023 claims; 50/50 shared savings against that baseline in year one; an 80%/120% risk corridor; and a 24-month term. The consortium has asked to widen scope to include spinal surgery, currently about £1.4m a year across the population, at the same capitation rate. The insurer's data shows wide regional variation in MSK referral rates, and 18% of the target population moved between regional providers in the last two years. The consortium is newly formed, holds no balance sheet beyond one year's operating costs, and has offered a virtual triage app at no extra cost.
1. Assess the incentive effects and design flaws in the proposed arrangement, including the arithmetic, and recommend changes.
Read the worked answer
The arithmetic first. £34 × 62,000 = £2.11m of capitation against a baseline of £3.1m. On paper the arrangement saves £0.99m before any clinical change, shared 50/50, so the consortium receives £2.60m. That is the first red flag: a third of the baseline 'saving' exists before anyone does anything.
Why. The £3.1m baseline is total MSK spend - GP consultations, imaging, orthopaedics, injections, drugs - while the consortium controls only physiotherapy. Savings will therefore be attributed to them even when they arise from another provider's behaviour, a coding change, or regression to the mean after an unusually high 2023. This is misattribution risk and it is the most likely source of a windfall.
Incentive effects. Capitation plus shared savings rewards under-provision and under-referral, particularly for patients who are expensive to treat. The 80/120% corridor limits downside but the provider has no balance sheet, so the downside is largely theoretical.
Scope expansion. Adding £1.4m of spinal surgery to a £2.11m capitation is not a pathway extension, it is transferring surgical risk to an undercapitalised counterparty at a rate that does not fund it. If activity rises, the insurer faces both the capitation and a provider failure.
Recommendations. Narrow the baseline to services the consortium actually controls; risk-adjust for age, morbidity and prior spend; increase the population and length of term to reduce volatility; replace 50/50 with a tiered share plus a withhold released against quality metrics; extend the corridor and require a performance bond; and decline the surgical scope, or tender it separately with a different risk-sharing structure.
2. How would you measure savings credibly, and what would you fix in the contract before signature?
Read the worked answer
Savings are a counterfactual, so the measurement rule must be agreed before the first patient is seen, not reconstructed afterwards.
Design.
- Define the comparison group: the non-contracted region, matched on age, sex, deprivation and prior MSK spend, or a pre-period trend with a control.
- Adjust for regression to the mean by using more than one baseline year, or a trimmed mean, since 2023 may have been an outlier.
- Strip out factors outside the provider's control: national tariff changes, drug price movements, a new imaging contract, coding changes, and the 18% population churn.
- Count total cost of care for the cohort, not just physiotherapy, and specify how out-of-area treatment and emergency admissions are attributed.
- Pre-specify the emergency and surgical escape routes so that the provider is not penalised, or rewarded, for urgent cases.
Contract fixes.
- Provider access to the measurement data only through an independent auditor with audit rights for the insurer - otherwise the consortium marks its own homework.
- A reconciliation timetable, a disputes process and a cap on total shared savings.
- Quality gates: patient-reported outcome measures, waiting times, re-referral and conversion-to-surgery rates, and a complaints route.
- Data protection terms under UK GDPR for the triage app, including purpose limitation and who is controller.
- Exit and step-in rights, and continuity of care provisions, given the consortium's thin balance sheet and the 24-month term.
- An explicit statement that the arrangement does not restrict members' access to other providers.
3. What governance, solvency and conduct risks would you raise with the insurer's board before it signs?
Read the worked answer
Counterparty and continuity. A newly formed consortium with one year of operating costs is a single point of failure for 62,000 members' MSK care. Ask for parent guarantees or a performance bond; test the scenario where the consortium fails in month nine; require novation and step-in rights and a documented transfer plan to alternative providers. Assess this under the insurer's outsourcing and operational resilience obligations.
Concentration. Fourteen practices across two regions is a small, correlated network. A dispute or a regulatory action against one practice could remove a large share of capacity.
Conduct and outcomes. Moving to capitation shifts the risk of under-treatment onto members. The board needs evidence that access is not being rationed: referral rates, waiting times, complaints, upheld complaints and outcomes by region. Under consumer-duty expectations the insurer must be able to show good outcomes for the cohort, not just a lower claims cost.
Conflicts and data. The consortium supplies the triage app, holds patient data, and benefits from the savings calculation. Segregate the data flows and the audit function.
Financial reporting and capital. Shared savings are contingent and should not be recognised in the best estimate until recoverable with reasonable certainty. The capitation is a fixed liability; the savings are not an asset of equivalent quality. Check the effect on the technical provisions and on the ORSA projections under the 120% corridor.
Recommendation to the board. Sign only with a narrowed baseline, risk adjustment, independent measurement, capital protection and quality gates; otherwise defer and re-tender.